• Inborn errors of metabolism

Elelyso Generic Name & Formulations

General Description

Taliglucerase alfa (recombinant) 200 Units; per vial; lyophilized pwd; for IV infusion after reconstitution; preservative-free.

Pharmacological Class

Lysosomal glucocerebroside-specific enzyme.

How Supplied

Single-use vial—1


Generic Availability


Elelyso Indications


Long-term enzyme replacement therapy (ERT) for patients with confirmed Type 1 Gaucher disease.

Elelyso Dosage and Administration

Adults and Children

<4yrs: not established. Give by IV infusion over 60–120 minutes. ≥4yrs: 60 Units/kg once every 2 weeks. Begin treatment with Elelyso at the same dose when switching from imiglucerase.

Elelyso Contraindications

Not Applicable

Elelyso Boxed Warnings

Not Applicable

Elelyso Warnings/Precautions


Have appropriate medical support available. Closely monitor patients during and after the infusion. Discontinue if anaphylaxis occurs and treat appropriately. Reduce or temporarily interrupt infusion, or administer antihistamines, corticosteroids and/or antipyretics if hypersensitivity reactions occur. Monitor for development of anti-drug antibodies. Pregnancy. Nursing mothers.

Elelyso Pharmacokinetics

See Literature

Elelyso Interactions

Elelyso Adverse Reactions

Adverse Reactions

Headache, arthralgia, fatigue, nausea, dizziness, abdominal pain, pruritus, flushing, vomiting, urticaria, extremity pain.

Elelyso Clinical Trials

See Literature

Elelyso Note

Not Applicable

Elelyso Patient Counseling

See Literature